NCT02059057TerminatedNot Applicable
Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066
Boston Scientific Corporation25 sites in 5 countries102 target enrollmentStarted: December 1, 2013Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 102
- Locations
- 25
- Primary Endpoint
- Mean Change in Six Minute Walk Test (6MWT)
Study Overview
Brief Summary
Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).
Detailed Description
Provide LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009, and obtain safety and effectiveness data on these patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 36 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject was enrolled as a Control Subject in and completed all required study assessments through the 12 month visit for the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN
- •Subject has post-bronchodilator FEV1 ≤45% predicted.
- •Subject has residual volume (RV) ≥175% predicted.
- •Subject has stopped smoking for at least 8 weeks prior to entering the study, as confirmed by a Cotinine test or other appropriate diagnostic test.
- •Subject has read, understood and signed the Informed Consent form.
- •Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
Exclusion Criteria
- •Subject has severe homogeneous emphysema as determined by the Core Radiology Lab
- •Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
- •Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator, unless investigator can confirm by other means that subject does not have asthma.
- •Subject has DLCO <20% of predicted.
- •Subject has severe gas exchange abnormalities as defined by:
- •PaCO2 >55 mm Hg PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)
- •Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
- •Subject has severe pulmonary hypertension. If pulmonary hypertension is present, "severe" is defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.
- •Subject has an inability to walk >140 meters (150 yards) in 6 minutes.
- •Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- •Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- •Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
- •Subject has clinically significant bronchiectasis.
- •Subject has giant bullae >1/3 lung volume.
- •Subject has had previous LVR surgery, lung transplantation, lobectomy, LVR devices or other devices to treat COPD in either lung.
- •Subject has been involved in pulmonary drug or device studies within 30 days prior to this study, with the exception of the RENEW Study.
- •Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.
- •Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
- •Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for seven (7) days prior to procedure.
- •Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.
- •Subject has a known sensitivity to drugs required to perform bronchoscopy.
- •Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
- •Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
Arms & Interventions
LVRC System
Experimental
Intervention: LVRC System (Device)
Outcomes
Primary Outcomes
Mean Change in Six Minute Walk Test (6MWT)
Time Frame: Change in Baseline to 12 months
Mean absolute change from baseline to12 months. The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.
Secondary Outcomes
- Mean Percent Change in Forced Expiratory Volume in One Second (FEV1)(Change in Baseline to 12 months)
- Mean Change in Residual Volume (RV)(Change in Baseline to 12 months)
- Mean Change in St. Georges Respiratory Questionnaire (SGRQ)(Change in Baseline to 12 months)
Investigators
Study Sites (25)
Loading locations...
Similar Trials
Completed
Phase 2
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological CancersUterine CancerAdvanced Gynecological CancersOvarian CancerCervical CancerNCT03073525Gradalis, Inc.25
Completed
Not Applicable
Lung Ultrasonography vs Fiberoptic Bronchoscopy for Aiding Lung Collapse in Patient Using Double Lumen TubeUltrasonographyThoracic SurgeryLung DiseasesOne Lung VentilationLung CollapseFiberoptic BronchoscopyNCT03314519Mahidol University200
Terminated
Not Applicable
Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure PatientsHeart FailureNCT02448342Sensible Medical Innovations Ltd.380
Completed
Not Applicable
Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT01020344University of Zurich30
Completed
Phase 2
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDIdiopathic Inflammatory MyositisMixed Connective Tissue DiseaseSclerodermaInterstitial Lung DiseaseNCT01862926Royal Brompton & Harefield NHS Foundation Trust104